The OCRP Proteogenomics Research Award mechanism is being offered for the first time in FY20.
The OCRP Proteogenomics Research Award supports the use of proteomics and/or genomics to explore new concepts or theories in ovarian cancer. The award is intended to support the genomic and/or transcriptomic and/or proteomic analysis of currently available clinical specimens with a focus on answering biologic and pathophysiologic questions of clinical relevance in ovarian cancer. The proposed research question should be innovative and have the potential to make an impact on ovarian cancer.
Clinical trials are not allowed under the Proteogenomics Research Award mechanism. The analysis of clinical trial-derived specimens and/or large patient specimen cohorts is encouraged. Preliminary data are not required but are allowed.
Applicants are encouraged to explore and consider the possible use of the unique proteomics resource at the Women’s Health Integrated Research Center (WHIRC) Clinical Proteomics Platform (CPP) which was established by the Department of Defense intramural Gynecologic Cancer Center of Excellence (GYN-COE) to provide cutting-edge capabilities for identifying and validating protein biomarkers and surrogates for enhanced cancer patient management through improved early detection, patient stratification, and monitoring for therapeutic efficacy, outcomes, and recurrence (for more information on the WHIRC Proteomics Capabilities, see Appendix 2).
Deadlines:
• Required Pre-Application Deadline: July 16, 2020
• Invited Application Submission Deadline: July 30, 2020
Investigators at the level of postdoctoral fellow or clinical fellow (or equivalent) and above may be named by the organization as the Principal Investigator (PI) on the application. An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.
The anticipated direct costs budgeted for the entire period of performance for an FY20 OCRP Proteogenomics Research Award will not exceed $250,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.
